Dr. Nageatte Ibrahim helped guide the clinical development of Keytruda, one of the most consequential immuno-oncology therapies
SCOTTSDALE, Ariz. — May 12, 2026 — Nageatte Ibrahim, M.D., an internationally recognized oncology drug development leader and immuno-oncology expert, has been appointed as Research Director of Developmental Therapeutics and Immuno-Oncology for HonorHealth Research Institute.
Starting May 18, during Melanoma Awareness Month, Dr. Ibrahim will help advance novel cancer therapies for patients, partner with oncologists across the HonorHealth system to expand access to clinical trials, and develop collaborations between the Research Institute and leading biomedical research centers worldwide.
“We are thrilled to welcome Dr. Ibrahim to HonorHealth Research Institute,” said Justin Moser, M.D., medical director of the Melanoma and Cutaneous Oncology Program at the Institute’s Oncology Research Division. “Her exceptional experience in oncology drug development and immuno-oncology will be instrumental as we continue to expand our clinical trial portfolio and bring cutting-edge therapies to patients who need them.”
Asked why she agreed to work at HonorHealth, Dr. Ibrahim said, “My career has been shaped by a commitment to ensuring that the most promising advances in cancer science are developed with the rigor, strategy, and urgency needed to reach patients. While oncology has made extraordinary progress, significant unmet needs remain across many cancers, and meeting those needs requires research that is both scientifically ambitious and deeply patient-centered.
“That is why HonorHealth’s mission resonates so strongly with me,” Dr. Ibrahim said. “I am honored to help advance a developmental therapeutics and immuno-oncology program focused not only on the next generation of cancer therapies, but on bringing those therapies closer to the patients who need them.”
Career spans global drug development
Dr. Ibrahim brings to HonorHealth Research Institute a distinguished career spanning academic oncology, translational research, and global cancer drug development. She trained in hematology and oncology, completed research fellowships in melanoma and breast cancer, and held faculty appointments at Harvard Medical School/Dana-Farber Cancer Institute and the University of Pennsylvania’s Perelman School of Medicine/Abramson Cancer Center.
She later established herself as a leader in biopharma oncology drug development, including as Vice President of Global Clinical Development, Oncology, at Merck, where she helped guide the strategy and execution of Keytruda and Keytruda-based combinations across multiple tumor types. Her work has supported major oncology advances and global approvals across melanoma, Merkel cell carcinoma, gastrointestinal and hepatobiliary cancers, and tumor-agnostic biomarker-driven indications, including MSI-H/dMMR and TMB-H cancers.
Dr. Ibrahim’s broader development experience spans immuno-oncology, targeted therapies, antibody-drug conjugates, and small molecules.
Leads drug development consulting
In 2025, Dr. Ibrahim founded Arc Nouvel Clinical Development Consulting, a boutique firm designed to help pharmaceutical, biotechnology, and investment clients navigate the complexity of modern oncology drug development. There, she assembled a distinguished network of clinical development experts, including colleagues with whom she has helped lead major immunotherapy advances, to provide strategic guidance, operational support, asset evaluation, and executive coaching across early- to late-stage programs.
She will continue her leadership at Arc Nouvel while serving at HonorHealth Research Institute, bringing to both roles a shared commitment to scientific rigor, operational excellence, and the development of new cancer therapies.
For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or email clinicaltrials@HonorHealth.com.
# # #
About the HonorHealth Research Institute
HonorHealth Research Institute is an international destination that is at the forefront of providing patients with a better quality of life through its clinical trials and innovative treatment options. Headquartered in Scottsdale, Arizona, the institute’s team of physicians and researchers collaborate with experts from across the nation to offer life-changing therapies, drugs and devices. At HonorHealth Research Institute, patients have access to tomorrow’s health innovations, today. Learn more at:https://honorhealthresearch.org/